RITUXAN SC 1400 MG / 11.7 ML
RITUXIMAB : 1400 MG / 11.7 ML · DIN 02457350 · HOFFMANN-LA ROCHE LIMITED
Health Canada status: MARKETED
What is RITUXAN SC?
RITUXAN SC 1400 MG / 11.7 ML contains RITUXIMAB : 1400 MG / 11.7 ML. It is listed in the Health Canada Drug Product Database under DIN 02457350, held by HOFFMANN-LA ROCHE LIMITED, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 22-Nov-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is RITUXAN SC used for?
RITUXAN (rituximab injection) is indicated for the treatment of patients with CD20 positive, diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) in combination with CHOP chemotherapy, the treatment of patients with previously untreated Stage III/IV follicular, CD20 positive, B-cell non-Hodgkin's lymphoma in combination with CVP chemotherapy, the maintenance treatment of patients with follicular non-Hodgkin’s lymphoma who have responded to induction therapy with either CHOP or CHOP plus Rituxan, and single-agent maintenance treatment of previously untreated patients with advanced follicular non-Hodgkin’s lymphoma with high tumour burden and who have responded to induction therapy with either CHOP plus Rituxan or CVP plus Rituxan. RITUXAN (rituximab injection) is also indicated for the treatment of patients with previously untreated or previously treated B-cell chronic lymphocytic leukemia (B-CLL), Binet Stage B or C, in combination with fludarabine and cyclophosphamide.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02457350 |
|---|---|
| Brand name | RITUXAN SC |
| Generic / active ingredient | RITUXIMAB : 1400 MG / 11.7 ML |
| Manufacturer | HOFFMANN-LA ROCHE LIMITED |
| Strength | 1400 MG / 11.7 ML |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | L01FA01 RITUXIMAB |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 22-Nov-2016 |
| Original market date | 2016-11-22 00:00:00 |
How is it stored and handled?
null
How is it supplied?
1400 mg/11.7 mL (in a 15 mL vial) for use in patients with non-Hodgkin’s lymphoma or 1600 mg/13.4 mL (in a 20 mL vial) for use in patients with chronic lymphocytic leukemia.
What can be used instead?
Other Canadian products sharing ATC code L01FA01 RITUXIMAB. 7 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| RITUXAN | 10 MG | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | DIN 02241927 |
| RITUXAN SC | 1600 MG / 13.4 ML | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | DIN 02473976 |
| RIXIMYO | 10 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02498316 |
| RUXIENCE | 10 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02495724 |
| TRUXIMA | 100 MG / 10 ML | SOLUTION | CELLTRION INC. | MARKETED | DIN 02478382 |
| TRUXIMA | 500 MG / 50 ML | SOLUTION | CELLTRION INC. | MARKETED | DIN 02478390 |
| RIABNI | 10 MG | SOLUTION | AMGEN CANADA INC | CANCELLED POST MARKET | DIN 02513447 |
Who else supplies RITUXIMAB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. RITUXIMAB appears in 128 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.